Elsevier

Metabolism

Volume 39, Issue 10, October 1990, Pages 1056-1062
Metabolism

In vitro studies on the action of CS-045, a new antidiabetic agent

https://doi.org/10.1016/0026-0495(90)90166-AGet rights and content

Abstract

The mechanism of action of CS-045, a new orally active antidiabetic agent, was studied in vitro using cultured hepatoma cells (Hep G2) and muscle cells (BC3H-1). Treatment of both types of cultured cells with varying doses of CS-045 did not significantly alter insulin receptor binding. Basal and insulin-stimulated glucose transport in BC3H-1 cells was also unaltered by the drug. In contrast, CS-045 increased glycogen synthase I activity in both cell types. This effect was maximal after 24 hours and in Hep G2 cells was associated with a threefold increase in the apparent affinity of the enzyme for glucose-6-phosphate. Gluconeogenesis from lactate in Hep G2 cells was greatly reduced by CS-045 treatment. We conclude that CS-045 may act directly on muscle and liver cells to increase glucose utilization. It is also effective in reducing glucose production. These multiple effects may account in part for the ability of CS-045 to reduce blood sugar levels in vivo.

References (50)

  • FQ Nuttall et al.

    Regulation of glycogen synthesis in the liver

    Am J Med

    (1988)
  • NS Shargill et al.

    Effect of ciglitazone on glucose uptake and insulin sensitivity in skeletal muscle of the obese (obob) mouse: Distinct insulin and glucocorticoid effects

    Metabolism

    (1986)
  • N Wollen et al.

    Inhibition of hepatic gluconeogenesis by metformin

    Biochem Pharmacol

    (1988)
  • DB Jacobs et al.

    Sulfonylurea potentiates insulin-induced recruitment of glucose transport carrier in rat adipocytes

    J Biol Chem

    (1985)
  • OG Kolterman et al.

    The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects

    Diabetes

    (1984)
  • G Reaven et al.

    Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturityonset diabetes mellitus

    Diabetes

    (1967)
  • WS Putnam et al.

    Selective potentiation of insulin-mediated glucose disposal in normal dogs by the sulfonylurea Glipizide

    J Clin Invest

    (1981)
  • LJ Mandarino et al.

    Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin dependent diabetes mellitus

    Diabetes Care

    (1984)
  • H Beck-Nielsen et al.

    Sulfonylureas improve insulin binding and insulin action in non-insulin dependent diabetes mellitus

    Diabetes Care

    (1984)
  • OG Kolterman et al.

    The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes

    Diabetes Care

    (1984)
  • G Ward et al.

    Gliclazide therapy is associated with potentiation of postbinding insulin action in obese non-insulin-dependent diabetic subjects

    Diabetes

    (1985)
  • J Bolinder et al.

    Reversal of insulin resistance in adipose tissue of non-insulin-dependent diabetics by treatment with diet and sulphonylurea

    Acta Endocrinol

    (1985)
  • ID Goldfine et al.

    Effect of biguanides and sulfonylureas on insulin receptors in cultured cells

    Diabetes Care

    (1984)
  • WE Fleug et al.

    Modulation by a sulfonylurea of insulin-dependent glycogenesis, but not of insulin binding, in cultured rat hepatocytes

    Diabetes

    (1984)
  • SS Solomon et al.

    Cyclic AMP phosphodiesterase in diabetes. Effect of glyburide

    Diabetes

    (1986)
  • Cited by (184)

    • Bone and fat

      2020, Marcus and Feldman’s Osteoporosis
    • Thiazolidine-2, 4-Dione: A Potential Weapon for Targeting Multiple Pathological Conditions

      2018, Key Heterocycle Cores for Designing Multitargeting Molecules
    • Thiazolidine-2,4-dione derivatives: Programmed chemical weapons for key protein targets of various pathological conditions

      2015, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      Thiazolidine-2,4-dione (TZD) is an important heterocyclic ring system that exhibit a range of pharmacological activities, but not limited to, including anti-hyperglycemic,1 anti-cancer,2 anti-arthritic,3 anti-inflammatory4 and anti-microbial,5 etc. Among them, anti-hyperglycemic is the widely studied effect of TZD derivatives that has also been extended to the development of clinically used ‘glitazone’ drugs such as rosiglitazone,6 pioglitazone,7 lobeglitazone8 and troglitazone,9 etc. The first ever pharmacological evaluation, that is, anti-TB activity, of any TZD derivative was reported by an Italian scientist ‘Vistentini’ in 195410 and following this, in the same year, Marshall and Vallance11 reported the anti-convulsing activity of other TZD derivatives.

    • Bone and Fat

      2013, Osteoporosis: Fourth Edition
    • Bone Marrow Fat and Bone Mass

      2013, Translational Endocrinology of Bone
    View all citing articles on Scopus

    Supported by a grant from Sankyo Company, Ltd.

    View full text